A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers-Reference-Cited by-同舟云学术

A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers

Published:2024-06-27 Issue:17 Volume:30 Page:3649-3651
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Silva-Pilipich Noelia¹²^ORCID,Smerdou Cristian¹²^ORCID

Affiliation:

1. Division of DNA and RNA Medicine, CCUN, Pamplona, Spain. 1

2. Instituto de Investigación Sanitaria de Navarra (IdISNA) and CCUN, Pamplona, Spain. 2

Abstract

Summary An oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 was tested in patients with advanced solid tumors. Antitumor effects were observed in both treated and non-treated lesions, leading to long-term survival in some patients. This clinical trial shows the potential of oncolytic virotherapy for patients refractory to standard therapies. See related article by Pakola et al., p. 3715

Funder

Fundacion Intheos

Departamento de Salud, Gobierno de Navarra

Instituto de Salud Carlos III

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-24-1126/3470494/ccr-24-1126.pdf

Reference9 articles.

1. Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial;Pakola;Clin Cancer Res,2024

2. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy;Havunen;Mol Ther Oncolytics,2017

3. Adenoviral delivery of tumor necrosis factor-α and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma;Siurala;Mol Ther,2016

4. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important?;Fausther-Bovendo;Hum Vaccin Immunother,2014

5. Clinical trial links oncolytic immunoactivation to survival in glioblastoma;Ling;Nature,2023